MY204827A - Semaglutide in medical therapy - Google Patents

Semaglutide in medical therapy

Info

Publication number
MY204827A
MY204827A MYPI2020001658A MYPI2020001658A MY204827A MY 204827 A MY204827 A MY 204827A MY PI2020001658 A MYPI2020001658 A MY PI2020001658A MY PI2020001658 A MYPI2020001658 A MY PI2020001658A MY 204827 A MY204827 A MY 204827A
Authority
MY
Malaysia
Prior art keywords
semaglutide
medical therapy
medicament
subject
need
Prior art date
Application number
MYPI2020001658A
Other languages
English (en)
Inventor
Maria Kabisch
Thomas Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY204827(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MY204827A publication Critical patent/MY204827A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MYPI2020001658A 2017-10-12 2018-10-10 Semaglutide in medical therapy MY204827A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17196254 2017-10-12
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Publications (1)

Publication Number Publication Date
MY204827A true MY204827A (en) 2024-09-18

Family

ID=60083831

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020001658A MY204827A (en) 2017-10-12 2018-10-10 Semaglutide in medical therapy

Country Status (18)

Country Link
US (4) US12029779B2 (enExample)
EP (1) EP3694538A1 (enExample)
JP (2) JP7148605B2 (enExample)
KR (1) KR20200069316A (enExample)
CN (4) CN119838000A (enExample)
AU (2) AU2018348929B2 (enExample)
BR (1) BR112020006246A2 (enExample)
CA (1) CA3078652A1 (enExample)
CL (1) CL2020000812A1 (enExample)
IL (3) IL322968A (enExample)
MA (1) MA50358A (enExample)
MX (3) MX2020003049A (enExample)
MY (1) MY204827A (enExample)
PH (1) PH12020550185A1 (enExample)
SG (1) SG11202002841PA (enExample)
TW (1) TWI842681B (enExample)
WO (1) WO2019072941A1 (enExample)
ZA (3) ZA202503387B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322968A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical treatment
MX2022009844A (es) * 2020-02-18 2022-09-05 Novo Nordisk As Composiciones y usos del peptido similar al glucagon-1 (glp-1).
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022212268A1 (en) * 2021-03-29 2022-10-06 Sanford Health Methods and compositions for treating lysosomal storage disorders
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
US20240404673A1 (en) * 2023-06-05 2024-12-05 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
PL3300721T5 (pl) 2003-11-20 2025-11-17 Novo Nordisk A/S Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania
ES2735533T3 (es) 2004-11-12 2019-12-19 Novo Nordisk As Formulaciones estables de GLP-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
KR101486829B1 (ko) 2005-09-14 2015-01-29 맨카인드 코포레이션 결정질 미립자 표면에 대한 활성제의 친화력의 증가를 기반으로 하는 약물 제제의 방법
BRPI0709964A2 (pt) 2006-04-14 2011-08-02 Mannkind Corp formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1)
WO2008116088A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
SI2373681T1 (sl) 2008-12-10 2017-05-31 Glaxosmithkline Llc Corporation Service Company Farmacevtski sestavki albiglutida
EA029759B1 (ru) 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
HUE027229T2 (en) 2009-12-16 2016-08-29 Novo Nordisk As Double acylated glp-1 derivatives
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
HRP20180425T1 (hr) 2010-12-16 2018-04-20 Novo Nordisk A/S Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
US8975223B2 (en) 2010-12-22 2015-03-10 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
JP6059802B2 (ja) * 2012-07-01 2017-01-11 ノヴォ ノルディスク アー／エス 長時間作用型ｇｌｐ−１ペプチドの使用
ES2688462T3 (es) * 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1
CN109715662B (zh) 2015-12-23 2023-07-21 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
IL322968A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical treatment

Also Published As

Publication number Publication date
IL322968A (en) 2025-10-01
CN119950682A (zh) 2025-05-09
SG11202002841PA (en) 2020-04-29
MA50358A (fr) 2020-08-19
JP2022132414A (ja) 2022-09-08
RU2020114960A (ru) 2021-10-28
CN111212657A (zh) 2020-05-29
KR20200069316A (ko) 2020-06-16
US12295988B2 (en) 2025-05-13
RU2020114960A3 (enExample) 2022-02-11
IL322969A (en) 2025-10-01
US20200237876A1 (en) 2020-07-30
US20240415935A1 (en) 2024-12-19
US20240316159A1 (en) 2024-09-26
JP7148605B2 (ja) 2022-10-05
MX2025002188A (es) 2025-04-02
ZA202503388B (en) 2025-09-25
ZA202503387B (en) 2025-09-25
WO2019072941A1 (en) 2019-04-18
CN119838000A (zh) 2025-04-18
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
IL273470A (en) 2020-05-31
US12029779B2 (en) 2024-07-09
PH12020550185A1 (en) 2021-03-01
AU2018348929A1 (en) 2020-05-07
TWI842681B (zh) 2024-05-21
EP3694538A1 (en) 2020-08-19
AU2018348929B2 (en) 2025-02-27
BR112020006246A2 (pt) 2021-03-30
ZA202503350B (en) 2025-09-25
CA3078652A1 (en) 2019-04-18
MX2025002189A (es) 2025-04-02
US20250235511A1 (en) 2025-07-24
CN120241968A (zh) 2025-07-04
TW201914611A (zh) 2019-04-16
JP7475398B2 (ja) 2024-04-26
JP2020536854A (ja) 2020-12-17
MX2020003049A (es) 2020-07-27

Similar Documents

Publication Publication Date Title
MY204827A (en) Semaglutide in medical therapy
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
PH12015502655A1 (en) Method
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
PH12017500617A1 (en) Dosage regimen for pegylated interferon
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
MX2022002038A (es) Composicion farmaceutica para el tratamiento del insomnio.
PH12015500915A1 (en) Bremelanotide therapy for female sexual dysfunction
MX2021003288A (es) Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica.
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности